Table 1 Clinical and pathological characteristics of neuroblastoma patients included in study cohorts: TARGET NBL, GSE85047, and E-MTAB-179.
From: Development and validation of a 21-gene prognostic signature in neuroblastoma
TARGET NBL | GSE85047 | E-MTAB-179 | |
|---|---|---|---|
(n = 243) | (n = 240) | (n = 416) | |
MYCN amplification status | |||
Amplified | 68 (28.0%) | 53 (22.1%) | 64 (15.4%) |
Not Amplified | 175 (72.0%) | 187 (77.9%) | 352 (84.6%) |
INSS Stage | |||
Stage 1 | 30 (12.3%) | 43 (17.9%) | 119 (28.6%) |
Stage 2 | 0 (0%) | 34 (14.2%) | 80 (19.2%) |
Stage 3 | 1 (0.4%) | 42 (17.5%) | 69 (16.6%) |
Stage 4 | 212 (87.2%) | 121 (50.4%) | 148 (35.6%) |
Age at diagnosis (days), median (range) | 1040 (6–7450) | 565 (0–7100) | 459 (0–8980) |
Follow-up for overall survival (days), median (range) | 1560 (2–5560) | 1230 (1–6460) | 1380 (8–6600) |
Overall survival events | 137 (55.6%) | 72 (30.0%) | 87 (20.9%) |
Follow-up for Event-free survival (days), median (range) | 715 (2–5560) | 813 (1–6460) | 1080 (8–6600) |
Event-free survival events | 134 (55.1%) | 94 (39.2%) | 140 (33.7%) |
